Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 505 - Generalized Pairwise Comparisons and Win Statistics (Win Ratio, Win Odds, and Net Benefit): A Ten-Year Journey
Type: Topic Contributed
Date/Time: Thursday, August 11, 2022 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #322825
Title: The Net Benefit as a Measure of Treatment Effect for Generalized Pairwise Comparisons
Author(s): Vaiva Deltuvaite-Thomas* and Marc Buyse
Companies: IDDI and IDDI
Keywords: generalized pairwise comparisons; Net treatment benefit; Win ratio; Win odds; benefit risk analysis; Time to event analysis
Abstract:

A very general and flexible statistical approach to the analysis of randomized clinical trials uses all pairwise comparisons between two patients, one taken from the treatment group and one from the control group. Each pair favors treatment (“win”), control (“loss”), or neither. The “net treatment benefit” is the difference between the proportion of wins and the proportion of losses. We will discuss some advantages of the net treatment benefit over the win ratio or the win odds using examples from oncology and rare diseases. When a delayed treatment effect is anticipated, e.g. when testing the effect of immunotherapies on survival time, the net benefit can incorporate thresholds of clinical relevance, expressed on the time scale, to increase power. When testing new treatments in orphan indications, the power of the test can also be increased by analyzing several outcomes, either by prioritizing them from most important to least important, or by considering them simultaneously when categorizing pairs as wins or losses. When testing new treatments that have substantial toxicities, generalized pairwise comparisons can be used to assess the benefit-risk balance of these treatments.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program